Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Cardiac troponin I as an early prognosis biomarker after trauma: a retrospective cohort study.

Decavèle M, Gault N, Gauss T, Pease S, Moyer JD, Paugam-Burtz C, Foucrier A.

Br J Anaesth. 2018 Jun;120(6):1158-1164. doi: 10.1016/j.bja.2018.03.010. Epub 2018 Apr 17.

2.

COBI (COntinuous hyperosmolar therapy for traumatic Brain-Injured patients) trial protocol: a multicentre randomised open-label trial with blinded adjudication of primary outcome.

Roquilly A, Lasocki S, Moyer JD, Huet O, Perrigault PF, Dahyot-Fizelier C, Seguin P, Sharshar T, Geeraerts T, Remerand F, Feuillet F, Asehnoune K; COBI group.

BMJ Open. 2017 Sep 24;7(9):e018035. doi: 10.1136/bmjopen-2017-018035.

3.

Super-refractory status epilepticus: epidemiology, early predictors, and outcomes.

Chateauneuf AL, Moyer JD, Jacq G, Cavelot S, Bedos JP, Legriel S.

Intensive Care Med. 2017 Oct;43(10):1532-1534. doi: 10.1007/s00134-017-4837-6. Epub 2017 May 11. No abstract available.

PMID:
28497271
4.

Immediate postoperative extubation in bilateral lung transplantation: predictive factors and outcomes.

Felten ML, Moyer JD, Dreyfus JF, Marandon JY, Sage E, Roux A, Parquin F, Cerf C, Zuber B, Le Guen M, Fischler M; Foch Lung Transplant Group.

Br J Anaesth. 2016 Jun;116(6):847-54. doi: 10.1093/bja/aew119.

5.

Simulation unmasks deficit in the knowledge of the WHO checklist among junior anaesthetists: Simulation scenario and survey.

Le Guen M, Moyer JD, Tesnieres A, Plaud B.

Eur J Anaesthesiol. 2016 Mar;33(3):224-6. doi: 10.1097/EJA.0000000000000362. No abstract available.

PMID:
26760403
6.

Left double-lumen tube with or without a carinal hook: A randomised controlled trial.

Dumans-Nizard V, Parquin JF, Moyer JD, Dreyfus JF, Fischler M, Le Guen M.

Eur J Anaesthesiol. 2015 Jun;32(6):418-24. doi: 10.1097/EJA.0000000000000201.

PMID:
25489763
7.

Tropomodulin 1-null mice have a mild spherocytic elliptocytosis with appearance of tropomodulin 3 in red blood cells and disruption of the membrane skeleton.

Moyer JD, Nowak RB, Kim NE, Larkin SK, Peters LL, Hartwig J, Kuypers FA, Fowler VM.

Blood. 2010 Oct 7;116(14):2590-9. doi: 10.1182/blood-2010-02-268458. Epub 2010 Jun 28.

8.

PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.

Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, Coleman K, Christensen JG, Emerson EO, Jakowski A, Hook K, Los G, Moyer JD, Pruimboom-Brees I, Pustilnik L, Rossi AM, Steyn SJ, Su C, Tsaparikos K, Wishka D, Yoon K, Jakubczak JL.

Mol Cancer Ther. 2010 Apr;9(4):883-94. doi: 10.1158/1535-7163.MCT-09-0915. Epub 2010 Mar 30.

9.

[Pleural talcage and peroperative detection of a second halogen gas: careful to 1,1,1,2 tetrafluoroethane].

Racine SX, Cherradi N, Moyer JD, Missaoui A, Baillard C.

Ann Fr Anesth Reanim. 2008 May;27(5):455-6. doi: 10.1016/j.annfar.2008.03.007. Epub 2008 May 8. French. No abstract available.

PMID:
18472387
10.

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.

Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK.

Cancer Res. 2007 Oct 15;67(20):9887-93.

11.

The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.

Lippa B, Kauffman GS, Arcari J, Kwan T, Chen J, Hungerford W, Bhattacharya S, Zhao X, Williams C, Xiao J, Pustilnik L, Su C, Moyer JD, Ma L, Campbell M, Steyn S.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3081-6. Epub 2007 Mar 19.

PMID:
17398092
12.

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD.

Clin Cancer Res. 2005 Mar 1;11(5):2063-73.

13.

Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.

Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ, Borie DC.

Science. 2003 Oct 31;302(5646):875-8.

14.

The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.

Barbacci EG, Pustilnik LR, Rossi AM, Emerson E, Miller PE, Boscoe BP, Cox ED, Iwata KK, Jani JP, Provoncha K, Kath JC, Liu Z, Moyer JD.

Cancer Res. 2003 Aug 1;63(15):4450-9.

15.

Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.

Bhattacharya SK, Cox ED, Kath JC, Mathiowetz AM, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Richter DT, Su C, Wessel MD.

Biochem Biophys Res Commun. 2003 Jul 25;307(2):267-73.

PMID:
12859950
16.
17.

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ.

J Pharmacol Exp Ther. 1999 Nov;291(2):739-48.

PMID:
10525095
18.

Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.

Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC, Yarden Y.

EMBO J. 1998 Oct 15;17(20):5948-63.

19.

ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.

Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, Andrews GC, Yarden Y.

Mol Cell Biol. 1998 Oct;18(10):6090-101. Erratum in: Mol Cell Biol 1998 Dec;18(12):7602. Alamandi M [corrected to Alimandi M].

20.

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P.

Cancer Res. 1997 Nov 1;57(21):4838-48.

21.

Bivalence of EGF-like ligands drives the ErbB signaling network.

Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y.

EMBO J. 1997 Aug 15;16(16):4938-50.

22.

Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.

Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, et al.

J Med Chem. 1995 Sep 15;38(19):3806-12.

PMID:
7562911
23.

The structural basis for the specificity of epidermal growth factor and heregulin binding.

Barbacci EG, Guarino BC, Stroh JG, Singleton DH, Rosnack KJ, Moyer JD, Andrews GC.

J Biol Chem. 1995 Apr 21;270(16):9585-9. Erratum in: J Biol Chem 1995 Nov 24;270(47):28494.

24.

Cyclopentenyl uracil: an effective inhibitor of uridine salvage in vivo.

Cysyk RL, Malinowski N, Marquez V, Zaharevitz D, August EM, Moyer JD.

Biochem Pharmacol. 1995 Jan 18;49(2):203-7.

PMID:
7840797
25.

Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185.

Miller P, Schnur RC, Barbacci E, Moyer MP, Moyer JD.

Biochem Biophys Res Commun. 1994 Jun 30;201(3):1313-9.

PMID:
7912926
26.

Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins.

Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD.

Cancer Res. 1994 May 15;54(10):2724-30.

27.

Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.

O'Dwyer PJ, Moyer JD, Suffness M, Harrison SD Jr, Cysyk R, Hamilton TC, Plowman J.

Cancer Res. 1994 Feb 1;54(3):724-9.

28.

Inhibitors of bombesin-stimulated intracellular signals: interruption of an autocrine pathway as a therapeutic strategy in small cell lung carcinoma.

Sausville EA, Trepel JB, Moyer JD.

Prog Clin Biol Res. 1990;354A:193-207. No abstract available.

PMID:
2174173
29.

Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase.

Kang GJ, Cooney DA, Moyer JD, Kelley JA, Kim HY, Marquez VE, Johns DG.

J Biol Chem. 1989 Jan 15;264(2):713-8.

30.

A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line.

Trepel JB, Moyer JD, Cuttitta F, Frucht H, Coy DH, Natale RB, Mulshine JL, Jensen RT, Sausville EA.

Biochem Biophys Res Commun. 1988 Nov 15;156(3):1383-9.

PMID:
2847733
31.

Modulation of bombesin-induced phosphatidylinositol hydrolysis in a small-cell lung-cancer cell line.

Trepel JB, Moyer JD, Heikkila R, Sausville EA.

Biochem J. 1988 Oct 15;255(2):403-10.

32.

Uptake and metabolism of myo-inositol by L1210 leukaemia cells.

Moyer JD, Malinowski N, Napier EA, Strong J.

Biochem J. 1988 Aug 15;254(1):95-100.

33.

Substrate properties of analogs of myo-inositol.

Moyer JD, Reizes O, Ahir S, Jiang C, Malinowski N, Baker DC.

Mol Pharmacol. 1988 Jun;33(6):683-9.

PMID:
2837638
34.
35.

A correlation of bombesin-responsiveness with myc-family gene expression in small cell lung carcinoma cell lines.

Sausville EA, Moyer JD, Heikkila R, Neckers LM, Trepel JB.

Ann N Y Acad Sci. 1988;547:310-21.

PMID:
2467598
36.
37.

D-myo-inositol (1,4)-bisphosphate 1-phosphate. Partial purification from rat liver and characterization.

Moyer JD, Reizes O, Dean NM, Malinowski N.

Biochem Biophys Res Commun. 1987 Aug 14;146(3):1018-26.

PMID:
3039989
38.
39.

Antitumor activity and biochemical effects of cyclopentenyl cytosine in mice.

Moyer JD, Malinowski NM, Treanor SP, Marquez VE.

Cancer Res. 1986 Jul;46(7):3325-9.

40.

The effect of 3-deazauridine and dipyridamole on uridine utilization by mice.

Moyer JD, Malinowski N, Cysyk RL.

Eur J Cancer Clin Oncol. 1986 Mar;22(3):323-7.

PMID:
2423341
41.

Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.

Moyer JD, Karle JM, Malinowski N, Marquez VE, Salam MA, Malspeis L, Cysyk RL.

Mol Pharmacol. 1985 Nov;28(5):454-60.

PMID:
2997596
42.

Salvage of circulating pyrimidine nucleosides by tissues of the mouse.

Moyer JD, Malinowski N, Ayers O.

J Biol Chem. 1985 Mar 10;260(5):2812-8.

43.

Salvage of uridine in the mouse. Effect of uridine phosphorylase pretreatment.

Moyer JD, Henderson JF.

Biochem Pharmacol. 1985 Jan 1;34(1):101-5.

PMID:
3966913
44.

Compartmentation of intracellular nucleotides in mammalian cells.

Moyer JD, Henderson JF.

CRC Crit Rev Biochem. 1985;19(1):45-61. Review.

PMID:
2416510
45.

Cyclopentenyluridine and cyclopentenylcytidine analogues as inhibitors of uridine-cytidine kinase.

Lim MI, Moyer JD, Cysyk RI, Marquez VE.

J Med Chem. 1984 Dec;27(12):1536-8. No abstract available.

PMID:
6094806
46.

Effect of an inhibitor of nucleoside transport on the disposition of uridine in mice.

Moyer JD, Paterson AR, Henderson JF.

Biochem Pharmacol. 1984 Jul 15;33(14):2327-9. No abstract available.

PMID:
6466355
47.
48.

Salvage of circulating hypoxanthine by tissues of the mouse.

Moyer JD, Henderson JF.

Can J Biochem Cell Biol. 1983 Nov;61(11):1153-7.

PMID:
6667423
49.

Nucleoside triphosphate specificity of firefly luciferase.

Moyer JD, Henderson JF.

Anal Biochem. 1983 May;131(1):187-9.

PMID:
6614450
50.

Ultrasensitive assay of RNA: application to 100-500 cells.

Moyer JD, Henderson JF, von Tigerstrom R.

Anal Biochem. 1983 May;131(1):190-3.

PMID:
6193729

Supplemental Content

Loading ...
Support Center